Osimertinib after surgery to stop leftover lung spots
Treatments studied
Part of Cancer clinical trials.
This study tests whether osimertinib can prevent remaining abnormal lung spots (called ground-glass nodules) from growing after surgery. It is for people with lung cancer caused by specific EGFR gene changes (L858R or exon 19 deletion).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to the study after being told what it involves (informed consent).
- You must be 30 to 75 years old and have lung adenocarcinoma confirmed by pathology (lab testing of tissue).
- Your lung scan must show one or more remaining ground-glass nodules in a different lung area (at least one other lobe).
- Your removed lung tumor must have an EGFR mutation limited to either L858R or exon 19 deletion.
- You must have had complete surgery for the main tumor and recover without major problems; your overall health score must be good (WHO 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This study tests whether a targeted therapy pill called osimertinib can help people whose lung cancer has returned after they already received targeted therapy following surgery. The goal is to see if this treatment can control the cancer and improve outcomes.
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
This study tests whether adding surgery to remove the main lung tumor improves outcomes for people with stage 4 lung cancer that has a specific EGFR mutation and only limited spread. If you qualify, you will take the targeted drug osimertinib for 12 weeks, and if the tumor responds, you may be randomly assigned to either continue the drug alone or have the main tumor surgically removed and then continue the drug.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
Hear when a new Lung Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.